Search results
Results from the WOW.Com Content Network
In July 2021, the U.S. Food and Drug Administration (FDA) approved Tanovea to treat lymphoma in dogs. [6] Lymphoma, also called lymphosarcoma, is a type of cancer that can affect many species, including dogs. [6] Rabacfosadine is the first conditionally approved new animal drug for dogs to achieve the FDA's full approval. [6]
The Consumer Health Product Database is a web-based application that allows the public to search for specific products or specific chemical ingredients. It is a collection of publicly available information, mostly from product labels and Safety Data Sheets (former MSDS) provided by the product's manufacturer. [ 1 ]
In the United States, the FDA approves drugs.Before a drug can be prescribed, it must undergo the FDA's approval process. While a drug can feasibly be used off-label (for non-approved indications), it still is required to be approved for a specific disease or medical condition. [2]
Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book, is a publication produced by the United States Food and Drug Administration (FDA), as required by the Drug Price and Competition Act (Hatch-Waxman Act). The Hatch-Waxman Act was created to '"strike a balance between two competing policy interests:
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
[1] [5] The US Food and Drug Administration (FDA) conditionally approved it in May 2023. [5] The reasonable expectation of effectiveness of Molidustat was evaluated in a study conducted in two phases. [5] The first phase involved a multi-center, double-masked, randomized, placebo-controlled field effectiveness and safety study. [5]
The Food and Drug Administration has finalized its decision to call an end to the drug shortage of Eli Lilly's blockbuster GLP-1 products, often referred to by their formula name, tirzepatide.Eli ...
ARIAD Pharmaceuticals, Inc. was founded in 1991 in Cambridge, Massachusetts by Harvey J. Berger, M.D. ARIAD raised $46 million as its initial financing in 1992, making it the single highest round of funding in the biotechnology industry at that time. [4]